Clinical utilization of four-factor prothrombin complex concentrate: a retrospective single center study
Objective Four-factor prothrombin complex concentrate (4F-PCC) was approved by the US Food and Drug Administration in 2013 for management of severely bleeding patients on warfarin therapy. We describe use of 4F-PCC at a large, suburban academic center. Methods We retrospectively reviewed all patient...
Main Authors: | Zaina Naeem, Salsabeel Allan, Aneury Hernandez, Dennis K Galanakis, Adam J. Singer |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Emergency Medicine
2021-06-01
|
Series: | Clinical and Experimental Emergency Medicine |
Subjects: | |
Online Access: | http://ceemjournal.org/upload/pdf/ceem-20-017.pdf |
Similar Items
-
Use of Prothrombin Complex Concentrate in the Emergency Department for Cases With Warfarin Overdose: A Retrospective Study
by: Filiz Baloglu Kaya, et al.
Published: (2020-12-01) -
Real-World Safety and Effectiveness of a 4-Factor Prothrombin Complex Concentrate in Japanese Patients Experiencing Major Bleeding: A Post-marketing Surveillance Study
by: Masahiro Yasaka, et al.
Published: (2024-02-01) -
Emergency management of major bleeding in a case of maxillofacial trauma and anticoagulation: utility of prothrombin complex concentrates in the shock room
by: Alessandro Morotti, et al.
Published: (2015-03-01) -
Precision medicine in hemostasis: a review of prothrombin complex concentrates and the role of viscoelastic tests in tailoring therapy
by: Iacopo Cappellini, et al.
Published: (2023-10-01) -
Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
by: Herm Jan M. Brinkman, et al.
Published: (2022-03-01)